U.S. markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.4400+0.1600 (+4.88%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close3.2800
Bid3.4300 x 2200
Ask3.6000 x 800
Day's Range3.1000 - 3.4900
52 Week Range1.7800 - 5.1400
Avg. Volume144,618
Market Cap339.877M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.9300
Earnings DateMar 11, 2024 - Mar 15, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ACIU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AC Immune SA
    Daily – Vickers Top Buyers & Sellers for 02/21/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    AC Immune Announces Upcoming Presentations at AD/PD™ 2024

    AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its preci

  • Zacks

    AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

    Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.

  • Zacks

    Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround

    The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.